{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:20:17Z","timestamp":1760242817412},"reference-count":103,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.blre.2016.04.006","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T13:57:16Z","timestamp":1462024636000},"page":"381-388","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?"],"prefix":"10.1016","volume":"30","author":[{"given":"Aziz","family":"Nazha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Prebet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Gore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1309\/AJCPJ71PTVIKGEVT","article-title":"Myelodysplastic\/myeloproliferative neoplasms","volume":"132","author":"Foucar","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.blre.2016.04.006_bb0010","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1097-0142(197105)27:5<1221::AID-CNCR2820270530>3.0.CO;2-P","article-title":"Myelomonocytic leukemia: disorderly proliferation of all marrow cells","volume":"27","author":"Saarni","year":"1971","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.blre.2016.04.006_bb0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French\u2013American\u2013British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2016.04.006_bb0020","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.04.006_bb0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2016.04.006_bb0030","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2016.04.006_bb0035","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2016.04.006_bb0040","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An international MDS\/MPN working group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.blre.2016.04.006_bb0045","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2016.04.006_bb0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2016.04.006_bb0055","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.3324\/haematol.2013.084061","article-title":"Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain","volume":"98","author":"Osca-Gelis","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2016.04.006_bb0060","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML\u2014dysplastic versus proliferative type","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.blre.2016.04.006_bb0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0145-2126(01)00014-5","article-title":"Dysplastic versus proliferative CMML\u2014a retrospective analysis of 91 patients from a single institution","volume":"25","author":"Nosslinger","year":"2001","journal-title":"Leuk Res"},{"issue":"16","key":"10.1016\/j.blre.2016.04.006_bb0070","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2013-03-491399","article-title":"Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2016.04.006_bb0075","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1182\/blood-2014-03-562637","article-title":"ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia","volume":"123","author":"Padron","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.10108","article-title":"Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes","volume":"70","author":"Boudard","year":"2002","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2016.04.006_bb0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00277-009-0835-2","article-title":"Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS)","volume":"89","author":"Economopoulou","year":"2010","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.blre.2016.04.006_bb0090","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2004-08-009498","article-title":"Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice","volume":"108","author":"Parikh","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.04.006_bb0095","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French\u2013American\u2013British cooperative leukaemia group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2016.04.006_bb0100","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2016.04.006_bb0105","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"7037","key":"10.1016\/j.blre.2016.04.006_bb0110","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.blre.2016.04.006_bb0115","first-page":"3","article-title":"Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera","volume":"64","author":"Pargade","year":"2006","journal-title":"Ann Biol Clin"},{"issue":"25","key":"10.1016\/j.blre.2016.04.006_bb0120","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.04.006_bb0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-8-299","article-title":"Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes","volume":"8","author":"Gelsi-Boyer","year":"2008","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.blre.2016.04.006_bb0130","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V93.6.2043.406k17_2043_2056","article-title":"Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice","volume":"93","author":"MacKenzie","year":"1999","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2016.04.006_bb0135","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.blre.2016.04.006_bb0140","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2016.04.006_bb0145","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2016.04.006_bb0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2016.04.006_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2012.064048","article-title":"Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia","volume":"98","author":"Kar","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2016.04.006_bb0160","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2016.04.006_bb0165","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2016.04.006_bb0170","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2016.04.006_bb0175","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2016.04.006_bb0180","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2010-07-295857","article-title":"Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies","volume":"117","author":"Tiu","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2016.04.006_bb0185","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2011.08631.x","article-title":"Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia","volume":"153","author":"Bacher","year":"2011","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.blre.2016.04.006_bb0195","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1182\/blood-2010-02-258558","article-title":"Nomenclature of monocytes and dendritic cells in blood","volume":"116","author":"Ziegler-Heitbrock","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2016.04.006_bb0200","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.04.006_bb0205","doi-asserted-by":"crossref","unstructured":"Orazi A, Germing U. The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22(7): 1308\u201319.","DOI":"10.1038\/leu.2008.119"},{"issue":"7","key":"10.1016\/j.blre.2016.04.006_bb0210","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3324\/haematol.2008.005421","article-title":"Morphological evaluation of monocytes and their precursors","volume":"94","author":"Goasguen","year":"2009","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.blre.2016.04.006_bb0215","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.blre.2016.04.006_bb0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1987.tb02291.x","article-title":"Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association","volume":"67","author":"Keene","year":"1987","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0225","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0165-4608(91)90142-H","article-title":"Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association","volume":"51","author":"Berkowicz","year":"1991","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0230","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2141.1992.tb06450.x","article-title":"Myelodysplastic syndrome associated with increased bone marrow fibrosis and translocation (5;12)(q33;p12.3)","volume":"82","author":"Lerza","year":"1992","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2016.04.006_bb0235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0165-4608(93)90051-M","article-title":"T(5;12)(q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia","volume":"65","author":"Wessels","year":"1993","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0240","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.blre.2016.04.006_bb0245","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/leu.2012.109","article-title":"RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation","volume":"26","author":"Ballerini","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2016.04.006_bb0250","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.blre.2016.04.006_bb0255","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2016.04.006_bb0260","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2016.04.006_bb0265","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2016.04.006_bb0270","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring system","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.blre.2016.04.006_bb0275","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2016.04.006_bb0280","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.blre.2016.04.006_bb0285","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2016.04.006_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.blre.2016.04.006_bb0295","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"S2","key":"10.1016\/j.blre.2016.04.006_bb0300","first-page":"S241","article-title":"Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome","volume":"45","author":"Symeonidis","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2016.04.006_bb0305","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.bbmt.2014.11.022","article-title":"Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia","volume":"21","author":"Duong","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2016.04.006_bb0310","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2016.04.006_bb0315","author":"Symeonidis","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2016.04.006_bb0320","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2008.366","article-title":"Outcome of allo-SCT for chronic myelomonocytic leukemia","volume":"43","author":"Ocheni","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2016.04.006_bb0325","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","article-title":"Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia","volume":"37","author":"Elliott","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0330","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0335","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.leukres.2011.09.001","article-title":"Treatment of polycythemia vera with imatinib mesylate","volume":"36","author":"Silver","year":"2012","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2016.04.006_bb0340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2016.04.006_bb0345","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.blre.2016.04.006_bb0350","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.blre.2016.04.006_bb0355","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2016.04.006_bb0360","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase II trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2016.04.006_bb0365","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.blre.2016.04.006_bb0370","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Fran\u00e7ais des My\u00e9lodysplasies and European CMML group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2016.04.006_bb0375","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01703109","article-title":"The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study","volume":"65","author":"Miller","year":"1992","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0380","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.2009.25.0209","article-title":"Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.blre.2016.04.006_bb0385","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2009.26.3509","article-title":"Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome","volume":"28","author":"Faderl","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2016.04.006_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2402330","article-title":"Thalidomide for the treatment of patients with myelodysplastic syndromes","volume":"16","author":"Strupp","year":"2002","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.blre.2016.04.006_bb0395","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1002\/cncr.26741","article-title":"A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) or primary myelofibrosis (PMF)","volume":"118","author":"Bejanyan","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2016.04.006_bb0400","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/10428190500353943","article-title":"Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes","volume":"47","author":"Raza","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2016.04.006_bb0405","doi-asserted-by":"crossref","unstructured":"Platzbecker U, Mohr B, von Bonin M, et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 21(11): 2384\u20135.","DOI":"10.1038\/sj.leu.2404811"},{"key":"10.1016\/j.blre.2016.04.006_bb0410","unstructured":"Cambier N, Wattel E, Menot ML, Guerci A, Chomienne C, Fenaux P. All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. Leukemia 10(7): 1164\u20137."},{"issue":"5","key":"10.1016\/j.blre.2016.04.006_bb0415","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","article-title":"Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid","volume":"104","author":"Kuendgen","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2016.04.006_bb0420","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.11262","article-title":"Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes","volume":"92","author":"Siitonen","year":"2007","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.blre.2016.04.006_bb0425","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-09-0494","article-title":"Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes","volume":"15","author":"Voso","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.blre.2016.04.006_bb0430","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00277-008-0536-2","article-title":"Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study","volume":"87","author":"Ravoet","year":"2008","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.blre.2016.04.006_bb0435","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2008.156","article-title":"On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2016.04.006_bb0440","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1021\/jm00113a034","article-title":"Nucleosides and nucleotides. 100. 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside","volume":"34","author":"Matsuda","year":"1991","journal-title":"Int J Med Chem"},{"issue":"7","key":"10.1016\/j.blre.2016.04.006_bb0445","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"NEJM"},{"issue":"3","key":"10.1016\/j.blre.2016.04.006_bb0450","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2002-01-0165","article-title":"Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene","volume":"100","author":"Magnusson","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2016.04.006_bb0455","first-page":"202","article-title":"CMML: a biologically distinct myeloproliferative disease","volume":"2","author":"Cortes","year":"2003","journal-title":"Curr Hematol Rep"},{"issue":"11","key":"10.1016\/j.blre.2016.04.006_bb0460","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.11416","article-title":"Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders","volume":"97","author":"Cortes","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.blre.2016.04.006_bb0465","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.11315","article-title":"Phase II study of SU5416\u2014a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor\u2014in patients with refractory myeloproliferative diseases","volume":"97","author":"Giles","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.blre.2016.04.006_bb0470","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.leukres.2013.01.014","article-title":"Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia","volume":"37","author":"Cilloni","year":"2013","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.blre.2016.04.006_bb0475","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00277-005-1031-7","article-title":"Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes","volume":"84","author":"Candoni","year":"2005","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.blre.2016.04.006_bb0480","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","article-title":"Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development","volume":"17","author":"Rowinsky","year":"1999","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2016.04.006_bb0485","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1182\/blood-2002-11-3359","article-title":"Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting","volume":"102","author":"Kurzrock","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2016.04.006_bb0490","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.2004.08.082","article-title":"Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome","volume":"22","author":"Kurzrock","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2016.04.006_bb0495","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/cncr.25575","article-title":"A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.blre.2016.04.006_bb0500","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","article-title":"A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome","volume":"109","author":"Fenaux","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2016.04.006_bb0505","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.leu.2403569","article-title":"Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia","volume":"19","author":"Buresh","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.04.006_bb0510","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.blre.2016.04.006_bb0515","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T08:40:33Z","timestamp":1600504833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X16300145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0268960X16300145"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2016.04.006","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2016.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}